You are here: Industry Insights > Humanigen

News List

Humanigen announces positive interim data of Lenzilumab in hospitalised COVID-19 patients expresspharma
November 09, 2020
The company intends to file for EUA in the first quarter of 2021 either following interim data at 75 per cent or at study completion.
Humanigen to enter Asia-Pacific market with Covid-19 drug pharmaceutical-technology
November 06, 2020
Humanigen has executed a licensing agreement with Telcon RF Pharmaceutical and KPM Tech for development and commercialisation rights of its Covid-19 drug lenzilumab for South Korea and the Philippines.
Humanigen announces first patient dosed in NIH ACTIV-5/Big Effect trial evaluating lenzilumab for Covid-19 pharmaceutical-business-review
November 04, 2020
Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that the first patient has been dosed at the Emory University School of Medicine in Atlanta, Georgia as...
Catalent, Humanigen Expand Lenzilumab Services Pact contractpharma
July 17, 2020
Catalent will provide development, manufacturing and commercialization services for Humanigen’s GM-CSF monoclonal antibody being studied in COVID-19.
Ajinomoto Bio-Pharma Partners with Humanigen contractpharma
May 28, 2020
Ajinomoto Bio-Pharma Services, a provider of biopharmaceutical contract development and manufacturing services, has entered into a manufacturing agreement with Humanigen Inc., for the fill finish supply of lenzilumab ...
Catalent Provides Clinical Support for COVID-19 Study contractpharma
May 11, 2020
Partners with Humanigen for FDA-approved Phase 3 lenzilumab study for COVID-19 patients.

Previous page 1 2 Next page